Think of Evinacumab as Another Niche Med for Lowering LDL

January 2024

Evinacumab (Evkeeza) will be a new injectable biologic for patients with a hereditary form of VERY high cholesterol.

It’s for patients with the most severe form of familial hypercholesterolemia...occurring in about 1 in 300,000 Canadians, with a slightly higher incidence in French Canadians.

These patients are at high risk for early cardiovascular events (heart attack, etc) or death from dangerously high cholesterol levels.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote